Immuron achieves record monthly Travelan® sales
13 sept. 2023 06h00 HE
|
Immuron Limited
Highlights: Record monthly Travelan® salesAustralian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron...
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
11 sept. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Immuron to present at the Military Health System Research Symposium
14 août 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it...
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
25 juil. 2023 06h00 HE
|
Immuron Limited
Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron CEO, Steven Lydeamore to present at Bioshares
24 juil. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief...
Immuron Business Update - Ateria Health launches Juvia™ in Australia
11 juil. 2023 06h00 HE
|
Immuron Limited
Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in AustraliaNew clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to...
Immuron FY23 Sales increase 136% on FY22 Sales
05 juil. 2023 06h00 HE
|
Immuron Limited
Highlights: Australian FY23 sales of A$1.16 M (478% increase on FY22 sales)USA FY23 Travelan® sales of A$643 k (28% increase on FY22 sales)Global FY23 sales of A$1.80 M (136% increase on FY22 sales) ...
Immuron Chairman Transition
30 juin 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the...
Immuron Business Update: Letter to Shareholders
22 juin 2023 06h00 HE
|
Immuron Limited
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Initiates Recruitment of Travelan® Clinical Study
30 mai 2023 06h00 HE
|
Immuron Limited
Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...